Adjuvant Oophorectomy versus CMF in Premenopausal Node-Positive Breast Cancer: Long-Term Results of an Experience at the Milan Cancer Institute

Abstract

Get full access to this article

View all access options for this article.

References

Bonadonna

, Valagussa

: Adjuvant systemic therapy for resectable breast cancer. J. Clin. Oncol., 3: 259–275, 1985.

Colleoni

, Coates

, Pagani

, Goldhirsh

: Combined chemo-endocrine adjuvant therapy for patients with operable breast cancer: still a question? Cancer Treat. Rev., 24: 15–26, 1998.

Early Breast Cancer Trialists’ Collaborative Group: Systemic treatment of early breast cancer by hormonal cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet, 339: 1–15, 71–85, 1992.

Scottish Cancer Trials Breast Group and ICRF Breast Unit:

Adjuvant ovarian ablation versus CMF chemotherapy in premenopausal women with pathological stage II breast carcinoma: The Scottish Trial.

Lancet, 341: 1293–1298, 1993.